NCT05347173View on ClinicalTrials.gov

Dexmedetomidine Versus Nalbuphine as an Adjuvant to Intrathecal Bupivacaine

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

January 30, 2024

Study Completion Date

March 12, 2024

Conditions
Analgesia
Interventions
DRUG

Dexmedetomidine

patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)

DRUG

Nalbuphine

patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)

Trial Locations (1)

35511

Mansoura University-Emergency hospital-ICU, El Dakahlia

All Listed Sponsors
lead

Mansoura University

OTHER